Black Diamond Therapeutics Inc Ordinary Shares BDTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
-
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
-
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
-
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
-
Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Trading Information
- Previous Close Price
- $3.66
- Day Range
- $3.60–3.82
- 52-Week Range
- $1.62–7.66
- Bid/Ask
- $3.75 / $3.80
- Market Cap
- $211.89 Mil
- Volume/Avg
- 493,484 / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 54
Comparables
Valuation
|
Metric
|
BDTX
|
ORIC
|
ACLX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.91 | 2.15 | 8.61 |
Price/Sales | — | — | 27.51 |
Price/Cash Flow | — | — | 507.02 |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BDTX
|
ORIC
|
ACLX
|
|---|---|---|---|
Quick Ratio | 6.67 | 14.66 | 5.85 |
Current Ratio | 6.87 | 15.08 | 6.01 |
Interest Coverage | — | — | −28.35 |
Quick Ratio
BDTX
ORIC
ACLX
Profitability
|
Metric
|
BDTX
|
ORIC
|
ACLX
|
|---|---|---|---|
Return on Assets (Normalized) | −46.40% | −31.05% | −1.88% |
Return on Equity (Normalized) | −62.87% | −33.92% | −3.31% |
Return on Invested Capital (Normalized) | −52.48% | −33.58% | −7.10% |
Return on Assets
BDTX
ORIC
ACLX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Shpkyxhr | Snjm | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Gzpzldx | Fswnjx | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jjnymfct | Dldvnq | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ldmgwnl | Jjfshm | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Plczdhv | Vpll | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Qldmqwwm | Cxzwh | $29.2 Bil | |||
| Moderna Inc
MRNA
| Ddnzxbw | Brkt | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Nwlcyhnq | Cwzy | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gxxsrxvp | Ktgcsy | $13.2 Bil | |||
| Incyte Corp
INCY
| Yjffyjl | Qxdzcgs | $13.0 Bil |
United States